A Practical Look at Cardiorenal Protection for CKD in T2D: Applying Recent Data

ReachMD Healthcare Image
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Optimal treatment with guideline-directed therapies, including RAS inhibitors, SGLT2 inhibitors, and nonsteroidal MRAs, is paramount in preventing progressive renal dysfunction and cardiorenal events in patients with chronic kidney disease and type 2 diabetes. As the patient becomes more complex, a multidisciplinary approach is often necessary to improve their outcomes. Listen in as our panel of experts offers strategies to improve collaboration and patient care.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Host:
    Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
    Senior Consultant Cardiologist, National Heart Centre Singapore
    Professor, Duke-National University of Singapore
    Singapore

    No relevant relationships reported

    Faculty:
    Maria Luiza Caramori, MD, PhD, MSc
    Associate Professor
    Department of Medicine and Department of Pediatrics
    University of Minnesota
    Minneapolis, MN

    Nothing to disclose

    Ana Maria Cebrián-Cuenca, MD, PhD
    Family Doctor
    Cartagena Casco Health Center
    Murcia, Spain

    Nothing to disclose

    Pam R. Taub, MD, FACC, FASPC
    Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
    Professor of Medicine
    UC San Diego Health System
    La Jolla, CA

    Consulting Fees: Amarin, Amgen, Bayer, Boehringer Ingelheim, Esperion, Medtronic, Novartis, Novo Nordisk, Sanofi
    Ownership Interest: Epirium Bio

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mario P. Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess the benefit-risk profiles of nonsteroidal mineralocorticoid receptor antagonists (MRAs) from recent studies of patients with chronic kidney disease (CKD) in type 2 diabetes (T2D)
    • Evaluate the potential impact of the latest clinical trial data on the real-world practice of addressing disease progression in a broad spectrum of patients with CKD in T2D 
    • Apply the ADA-KDIGO consensus recommendations and other guidelines (ADA, AHA, ESC) when planning treatment for a patient with CKD in T2D
    • Identify safety considerations for the proper monitoring of nonsteroidal MRA use in patients with CKD in T2D
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, cardiologists, primary care physicians, endocrinologists, and diabetologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

     

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Bayer AG.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying Medtelligence…
but how about a more personalized experience?

Register for free